RedHill Buys Commercialization Rights to Ferring's Rebyota and Clenpiq
RedHill Biopharma acquired exclusive commercialization rights to Ferring's Rebyota and Clenpiq for a $12 million upfront payment plus milestones and royalties, funded by its $18 million Talicia divestiture.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.